Pharmaceuticals, Biotechnology and Life Sciences
Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc.…
– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented…
– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented…
DUBLIN–(BUSINESS WIRE)–The “Global Biotechnology Congress 2019 – Academic” conference has been added to ResearchAndMarkets.com’s offering. The Global Biotechnology Congress (GBC…
DUBLIN–(BUSINESS WIRE)–The “Pompe Disease: Opportunity Analysis and Forecasts to 2027” report has been added to ResearchAndMarkets.com’s offering. It is estimated…
DUBLIN–(BUSINESS WIRE)–The “Pompe Disease: Opportunity Analysis and Forecasts to 2027” report has been added to ResearchAndMarkets.com’s offering. It is estimated…
ANN ARBOR, Mich.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24KBLB&src=ctag" target="_blank"gt;$KBLBlt;/agt; lt;a href="https://twitter.com/hashtag/KBLB?src=hash" target="_blank"gt;#KBLBlt;/agt;–Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider…
The International Liver Cancer Association (ILCA) Annual Conference has selected the Can-Fite abstract for presentation Phase III trial for Namodenoson…
The International Liver Cancer Association (ILCA) Annual Conference has selected the Can-Fite abstract for presentation Phase III trial for Namodenoson…
STAMFORD, Conn.–(BUSINESS WIRE)–SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and…